SYNNOVATION THERAPEUTICS

SYNNOVATION THERAPEUTICS logo

Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets. The company was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics. Synnovation’s pipeline is built around highly validated precision oncologic targets where greater potency and selectivity and optimized pharmaceutical properties have the potential to address liabilities in existing standards of care, and meaningfully improve patient outcomes. The company’s lead program, SNV1521, is a best-in-class potent, selective and CNS penetrant PARP1 inhibitor is in a Phase I study.

AboutPrivacyTerms